News

STAT4h
4 takeaways from the MAHA commission’s report on children’s health
The MAHA commission's assessment of children's health mirrored RFK Jr.'s familiar targets. The question now is what remedies ...
GSK's asthma drug Nucala wins FDA's approval to treat 'smoker's lung'
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...
GSK's asthma drug wins FDA approval to treat 'smoker's lung'
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...
Medscape23h
Single-Dose Intravenous Salbutamol Bolus for Managing Children With Acute Severe Asthma in the Emergency Department: Reanalysis of Data
After clinical evaluation, patients who had severe asthma were given high-dose inhaled salbutamol and had an intravenous cannula inserted. Additional treatment consisted of intravenous ...
PharmiWeb19h
Inhalation and Nasal Spray Generic Drugs Market is anticipated to reach USD 49.01 Billion by 2033 at a CAGR of 8.96% | FMI
The global inhalation and nasal spray generic drugs market is projected to have a moderate-paced CAGR of 8.96% during the forecast period. The current valuation of the inhalation and nasal spray ...
The American Journal of Managed Care4h
FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype
FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.